Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL2 | P60568 | 17/20 | 0.65 |
| ▸ | TNF | P01375 | 1/20 | 0.54 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.54 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.54 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16650120 | 0.91 | IL2 (0.71) | IL2TNFSTIM1ORAI1 | |
| SCHEMBL15528438 | 0.91 | IL2 (0.75) | IL2TNFSTIM1ORAI1 | |
| SCHEMBL15528261 | 0.90 | IL2 (0.64) | IL2TNFSTIM1ORAI1SCN5A | |
| SCHEMBL15528635 | 0.86 | IL2 (0.70) | IL2TNFSTIM1ORAI1 | |
| SCHEMBL16650474 | 0.86 | IL2 (0.69) | IL2TNFSTIM1ORAI1 | |
| SCHEMBL15528326 | 0.86 | IL2 (0.68) | IL2TNFSTIM1ORAI1 | |
| SCHEMBL15528177 | 0.86 | IL2 (0.66) | IL2TNFSTIM1ORAI1 | |
| SCHEMBL16650477 | 0.86 | IL2 (0.65) | IL2TNFSTIM1ORAI1SCN9A | |
| SCHEMBL15528398 | 0.85 | IL2 (0.61) | IL2TNFSTIM1ORAI1 | |
| SCHEMBL15528349 | 0.85 | STIM1 (0.50) | IL2TNFSTIM1ORAI1NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160304506-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-10-20 | — | — | US | claimed |
| US-20150111900-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2015-04-23 | — | — | US | claimed |
| EP-2844655-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS | Lupin Limited (IN) | 2015-03-11 | — | — | EP | claimed |
| WO-2013164769-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2013-11-07 | — | — | WO | claimed |
| US-20160304506-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-10-20 | — | — | US | disclosed |
| US-20160304506-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-10-20 | — | — | US | disclosed |
| US-9399638-B2 | Substituted pyridine compounds as CRAC modulators | LUPIN LIMITED (IN) | 2016-07-26 | — | — | US | disclosed |
| US-9399638-B2 | Substituted pyridine compounds as CRAC modulators | LUPIN LIMITED (IN) | 2016-07-26 | — | — | US | disclosed |
| US-20150111900-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2015-04-23 | — | — | US | disclosed |
| US-20150111900-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111900-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS | ORAI1, RYR2, RYR1 | IL2 2982/4885TNF 2731/4885STIM1 29/4885 |
| US-20160304506-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS | ORAI1, RYR2, RYR1 | IL2 2982/4885TNF 2731/4885STIM1 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.